Chinese medicine exports hit a wall

Over the years, due to foreign "green barriers", Chinese traditional medicine exports have run into trouble. As a traditional Chinese medicine giant, China's export volume of traditional Chinese medicine accounts for only 3% to 5% of the world's traditional Chinese medicine market. What is even more worrying is that the foreign pharmaceutical companies that import herbal extracts from China have become high-priced products of “Chinese medicine” after deep processing abroad.

According to the statistical data of China Pharmaceutical (19.19, 0.47, 2.51%) Health Products Import and Export Chamber of Commerce, the export volume of plant extracts in the first quarter of 2013 reached US$330 million, an increase of 11.2% year-on-year, accounting for 47% of the total exports of Chinese medicines. %. In recent years, China's export volume of plant extracts has been increasing year by year. In 2010, it was 820 million US dollars, exceeded 1 billion US dollars in 2011, and reached 1.16 billion US dollars in 2012. These plant extracts were processed into higher added-value “Chinese herbal medicines” after being exported. "Most of them were sold to China, the world's largest consumer of traditional Chinese medicine.

According to the media, Japan Jiuxin Pharmaceutical Co., Ltd., which uses the traditional Chinese medicine Liushen Pill, has achieved hundreds of millions of US dollars in sales each year, and most of these sales come from China. Germany imports large quantities of cheap Ginkgo biloba leaves from China each year, and the products produced are then sold back to China at a price 10 times higher than the original value. According to incomplete statistics, "Chinese medicine" has already accounted for one-third of the Chinese proprietary Chinese medicine market.

Inspired by the success of Kamsuke Pharmaceutical Co., Ltd. and other Japanese companies to promote Kampo medicine, more and more multinational corporations are looking for R&D and investment opportunities in Chinese medicine. GSK, currently trapped in bribery, has publicly stated that its research and development center in Shanghai will start research and development of Chinese medicine. At the beginning of this year, Li Jieshi, the giant of the fast-moving consumer goods industry in the UK, has announced the acquisition of Gui Long Pharmaceutical, a traditional Chinese medicine company.

The traditional Chinese medicine industry has always been China's traditional advantageous industry. It has a long history of thousands of years and is a treasure of the Chinese nation. Over the years, Chinese medicine has occupied half of China's pharmaceutical industry because of its advantages of high yield, wide distribution, and low toxic and side effects. However, on the other hand, our country pays less attention to the Chinese medicine industry, and the technical standard system of the Chinese medicine industry is not perfect, which leads to the slow development of the Chinese medicine industry and the difficulty in the internationalization of Chinese medicine.